Are there Time-period-related Differences in the Prophylactic Effects of Bacille Calmette-Guérin Intravesical Instillation Therapy in Japan?

Takehiko Okamura1*, Ryosuke Ando1, Hidetoshi Akita1, Yoshihiro Hashimoto2, Yutaka Iwase2, Taku Naiki3, Noriyasu Kawai3, Keiichi Tozawa3, Kenjiro Kohri3

Abstract

Objective: The guidelines on indications for prophylactic use of Bacille Calmette-Guérin (BCG) against non-muscle-invasive bladder cancer (NMIBC) have changed over the years. In order to assess the impact on outcome, the present retrospective comparison of BCG efficacy by time period with Japanese patients was conducted.

Patients and Methods: A total of 146 cases of NMIBC treated with BCG since February 1985 were retrospectively evaluated. All patients received 80 mg of BCG (Tokyo 172 strain) six to eight times a week for prophylactic use. Comparison was made among three historical groups (Group A: 1980’s, 39 cases; Group B: 1990’s, 61 cases; Group C: 2000’s, 46 cases).

Results: In total, recurrence was seen in 55 of the 146 cases (37.7%), and progression in 14 (9.6%), 1 patient dying of cancer. These overall results were similar to those outlined in previous reports. However, the outcomes of this time-period-based analysis indicated a tendency for a shorter time to recurrence in patients after 2000, although a log-rank test showed no significance (P=0.229). Seven of the cases featuring progression (i.e., half of all such cases) were among the 46 Group C patients (15.2%). Excluding these progressive cases, there was no significant difference among the remaining 132 patients in the three groups.

Conclusion: This study results revealed a tendency for a lower non-recurrence rate after 2000 in our series. This could stem from a number of factors, including changes in BCG indication criteria and the evolution of histopathological diagnostic criteria.

Keywords: Bacille Calmette-Guérin - non-muscle-invasive bladder cancer - time period - Japanese patients
BCG 6-8 times once a week for prophylaxis. The age range was from 36-85 (average 66.7), with a male: female ratio of 126:20 (86.3%:13.7%). All patients had a history of either multifocal and/or recurrent stage Ta or T1 papillary urothelial carcinoma (UC) (Ta:T1=71.75, without any other concurrent malignancies or active tuberculosis infection. Tumor grades were G1/G2/G3=35(24.0%)/84(57.5%)/27(18.5%), and numbers were single/2-3/4 or more =36(24.7%)/41(28.0%)/69(47.3%). Recurrence and non-recurrence cases were 68(46.6%) and 78(53.4%) respectively, before the initial BCG treatment. The 146 cases were divided into three historical groups (Group A: 1980’s, 39 cases; Group B: 1990’s, 61 cases; and Group C: 2000’s, 46 cases), for inter-comparison.

BCG treatment was terminated before the course of 6-8 instillations could be performed in a number of cases, but a minimum of 4 applications was performed in all. The patients were asked to refrain where possible from urination within two hours of the instillation and were monitored for bladder irritation, temperature change and other clinical symptoms. A tuberculin test, blood examinations, chest X-rays, cystoscopy and urinary cytology were conducted in all cases prior to BCG instillation and also at other times when considered appropriate.

Follow up was performed once a week during the weekly treatment periods, and then every 1-3 months after cessation of treatment, depending on the patients’ situation. Recurrence with progression was defined with reference to muscle invasive disease (Schwaibold et al., 2006). Recurrence free survival was defined as the period elapsed between the last BCG induction instillation.

Surgically resected materials were routinely fixed in 10% buffered formalin and embedded in paraffin for sectioning and histopathological assessment of hematoxylin and eosin stained sections. Tumor grading and staging were performed with reference to the 3rd edition of the “General Rules for Clinical and Pathological Studies on Bladder Cancer of the Japanese Urological Association and the Japanese Society of Pathology”.

Univariate statistical analyses were accomplished using Fisher’s exact test, and multivariate analyses were conducted with Cox’s hazard model. Cumulative non-recurrence rates were estimated using the Kaplan-Meier method, and the significance of differences between curves was tested by the Log-rank test. A value of p<0.05 was considered statistically significant. Simple linear regression analysis was used to determine the correlation coefficient between the period of BCG treatment and clinical variables. All the statistical analyses were performed using SPSS Version 17.

### Results

In total, recurrence was seen in 55 of the 146 cases (37.7%). Three and 5 year recurrence free rates were 69.9% and 64.7%. This result was similar to those outlined in previous and recent reports (Okamura et al., 1996; Smith et al., 1999; Oosterlinck et al., 2001; Martínez-Piñeiro et al., 2005; Margel et al., 2007; Ojea et al., 2007; Sylvester et al., 2011; Maurizio et al., 2012; Cho et al., 2012; Librenjak et al., 2012; Meijer et al., 2012; Segal et al., 2012). Patient characteristics of each group are summarized in Table 1. Instillation time was decreased from the 1990’s, dose was reduced, T1 stage was decreased, and multiple tumor cases increased over the three time periods, all demonstrating significant alteration. Figure 1 illustrates recurrence free

### Table 1. Patients’ Characteristics of BCG Treatment in Three Different Age Groups

<table>
<thead>
<tr>
<th>Categories</th>
<th>1980’s N=39</th>
<th>1990’s N=61</th>
<th>2000’s N=46</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age Median (Range)</td>
<td>67(36-85)</td>
<td>67(44-83)</td>
<td>68.5(50-83)</td>
<td>0.27</td>
</tr>
<tr>
<td>Gender Male : Female</td>
<td>32:07:00</td>
<td>55:06:00</td>
<td>39:07:00</td>
<td>0.483</td>
</tr>
<tr>
<td>Instillation time ≤5 : ≤5</td>
<td>0:39</td>
<td>9:52</td>
<td>3:43</td>
<td>0.028*</td>
</tr>
<tr>
<td>Dose 40mg : 60mg : 80mg</td>
<td>0:00:39</td>
<td>1:02:58</td>
<td>21:07:18</td>
<td>0.000*</td>
</tr>
<tr>
<td>Grade G1 : G2 : G3</td>
<td>13:18:08</td>
<td>12:35:14</td>
<td>10:31:05</td>
<td>0.212</td>
</tr>
<tr>
<td>Stage pTa : pT1</td>
<td>12:27</td>
<td>27:34:00</td>
<td>32:14:00</td>
<td>0.001*</td>
</tr>
<tr>
<td>Single/Multiple</td>
<td>13:26</td>
<td>15:46</td>
<td>7:39</td>
<td>0.148</td>
</tr>
<tr>
<td>Number of tumors 1 : 2-3 : 4 or more</td>
<td>13:10:16</td>
<td>15:25:21</td>
<td>8:06:32</td>
<td>0.002*</td>
</tr>
<tr>
<td>Primary/Recurrent</td>
<td>21:18</td>
<td>29:32:00</td>
<td>18:28</td>
<td>0.391</td>
</tr>
</tbody>
</table>

*significantly different
In our study, the results indicated a tendency for a lower non-recurrence rate since 2000, which might be related to differences in the background characteristics, like greater average numbers of tumors per case, increased low dose cases in the 2000’s. We believe that this finding is the first such report in the literature concerning BCG intravesical instillation therapy.

Clearly, a number of factors might account for our findings. In the 1980’s, BCG was introduced as a promising treatment option for recurrent NMIBC (the initial term being superficial bladder cancer). Therefore BCG became used worldwide, but many severe adverse effects were reported, including anaphylactic shock, arthritis, Reiter’s syndrome, general tuberculosis infection, and contracted bladder. In view of this evidence, applied doses have been reduced (Ojea et al., 2007; Yoneyama et al., 2008) as was also shown by our data. However, most dose-dependent comparisons showed no variation in efficacy with the dose (Martínez-Piñeiro et al., 2005; Sylvester et al., 2011). BCG indication criteria have also been changed so that more strict attention to the selected patients has been given year by year in the US and other countries (AUA, EAU, NCCN guidelines) (http://www.nccn.org; http://www.uroweb.org; http://www.auanet.org). Japan also has changed the applied criteria (bladder cancer practice guideline: Japanese Urological Association: 2009). Our analysis of 22 BCG bladder instillation papers dealing with Japanese patients (Tachibana et al., 1989; Yamamoto et al., 1990; Yabusaki et al., 1991; Ozono et al., 1992; Ao et al., 1993; Kano et al., 1993; Tachibana et al., 1993; Irie et al., 1994; Tanaka et al., 1994; Takashi et al., 1995; Ao et al., 1996; Ozono et al., 1997; Tozawa et al., 2001; Irie et al., 2003; Hinotsu et al., 2006; Kikuchi et al., 2009; Segawa et al., 2009; Hinotsu et al., 2011) revealed a similar tendency for lower 3-year non-recurrence with year of starting BCG treatment as found here (see Fig. 2). Change of histopathological bladder cancer grading and staging criteria could clearly exert an influence and the distinction between high malignant potential and non-invasive low malignant potential tumors has received more emphasis. Consequently, the name of superficial bladder cancer has been changed to NMIBC and in Japan the applied criteria (bladder cancer practice guideline: Japanese Urological Association: 2009). Our analysis of 22 BCG bladder instillation papers dealing with Japanese patients (Tachibana et al., 1989; Yamamoto et al., 1990; Yabusaki et al., 1991; Ozono et al., 1992; Ao et al., 1993; Kano et al., 1993; Tachibana et al., 1993; Irie et al., 1994; Tanaka et al., 1994; Takashi et al., 1995; Ao et al., 1996; Ozono et al., 1997; Tozawa et al., 2001; Irie et al., 2003; Hinotsu et al., 2006; Kikuchi et al., 2009; Segawa et al., 2009; Hinotsu et al., 2011) revealed a similar tendency for lower 3-year non-recurrence with year of starting BCG treatment as found here (see Fig. 2).

Change of histopathological bladder cancer grading and staging criteria could clearly exert an influence and the distinction between high malignant potential and non-invasive low malignant potential tumors has received more emphasis. Consequently, the name of superficial bladder cancer has been changed to NMIBC and in Japan the pathological classification modified from T1a and T1b to T1 only in the 1990’s. However, in our series the more recent cases were more likely to be T1a rather than T1, contrary to expectation from the lower non-recurrence rate.

Increasing patient age is another possible factor and in our series, patients’ age overall was significantly different between recurrence and non-recurrence cases (P=0.023). In fact patients’ age at BCG application has shown a tendency of increase in the 22 Japanese papers we analyzed (Tachibana et al., 1989; Yamamoto et al., 1990; Yabusaki et al., 1991; Ozono et al., 1992; Ao et al., 1993; Kano et al., 1993; Tachibana et al., 1993; Irie et al., 1994; Tanaka et al., 1994; Takashi et al., 1995; Ao et al., 1996; Ozono et al., 1997; Tozawa et al., 2001; Irie et al., 2003; Hinotsu et al., 2006; Kikuchi et al., 2009; Segawa et al., 2009; Hinotsu et al., 2011). Fig 3 shows a
tendency for increase in more elderly patients receiving BCG treatment over time. There have been published several papers of less efficacy of BCG for elderly patients including our own report (Joudi et al., 2006; Kohjimoto et al., 2010; Okamura et al., 2010; Margel et al., 2011). This point could be supportive in our speculation.

To increase the efficacy of BCG maximally, BCG treatment recommendation or guideline could be more soften for the patients with multiple recurrent low grade tumors, who refused surgery, or who cannot perform surgery for severe complications, because many urologists have been used to adverse effects of BCG these days. On the other hand, long-term outcome of efficacy treated with high-risk NIBC has been reported as poor prognosis, and the author suggested that rethinking the paradigm shift of this disease very recently (Thomas et al., 2012).

In conclusion, this study results revealed a trend showing a low non-recurrence rate since 2000 in Japan. This is thought to stem from a number of factors, including changes in BCG indication criteria and the evolution of histopathological diagnostic criteria.

References


http://www.auanet.org/content/clinical-practice-guidelines/clinical-guidelines.cfm?sub=bc


http://www.uroweb.org/gls/pdf/05_TaT1_Bladder_Cancer_LR%20March%2013th%202012.pdf


we identify patients for early cystectomy? BJU Int, 109, 1026-1030.


